NCT01265758

Brief Summary

The purpose of this study is to assess efficacy of prolonged Full Disclosure electrocardiogram (ECG) monitoring and signal analysis using advanced telemetric technology in comparison with a standard Holter ECG recording and an Event Holter recording to diagnose cardiac arrhythmia.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
360

participants targeted

Target at P75+ for not_applicable atrial-fibrillation

Timeline
Completed

Started Feb 2011

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 21, 2010

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 23, 2010

Completed
1 month until next milestone

Study Start

First participant enrolled

February 1, 2011

Completed
3.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2014

Completed
Last Updated

February 20, 2013

Status Verified

February 1, 2013

Enrollment Period

3.1 years

First QC Date

December 21, 2010

Last Update Submit

February 18, 2013

Conditions

Keywords

Atrial fibrillationCardiac arrhythmiaECGTelemonitoringTelemetryHolter

Outcome Measures

Primary Outcomes (1)

  • Recording of symptomatic or life threatening arrhythmia event

    ECG monitoring is conducted until occurrence of symptomatic arrhythmia or life threatening arrhythmia but not longer than 14 days. Patients in the control group will have standard ECG Holter monitoring repeated 3 times unless arrhythmia is diagnosed earlier.

    14 days

Secondary Outcomes (3)

  • Quality of Life questionnaire and European Heart Rhythm Association (EHRA) scale assessment against evidence of cardiac arrhythmia occurrence.

    14 days

  • Silent (asymptomatic) arrhythmia events incidence detection assessment

    14 days

  • Evaluation of stroke and bleeding risk factors incidence

    14 days

Study Arms (2)

Telemetric ECG monitoring

EXPERIMENTAL

Telemetric 14-days Full Disclosure ECG recording.

Device: Prolonged telemetric Full Disclosure ECG recording.

Standard 24-hours Holter ECG recording

ACTIVE COMPARATOR

Standard 24-hours Holter ECG recording repeated 3 times unless arrhythmia is diagnosed earlier.

Device: Prolonged telemetric Full Disclosure ECG recording.

Interventions

Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days

Also known as: Medicalgorithmics, PocketECG
Standard 24-hours Holter ECG recordingTelemetric ECG monitoring

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age - between 18 and 80 years old
  • History of symptoms potentially caused by arrhythmia
  • Symptoms occuring at least monthly
  • Patient informed consent
  • Declarative and feasible compliance (patient understands basic instructions regarding device use)

You may not qualify if:

  • Evidence of previously recorded arrhythmia
  • Inability to comply with the study protocol
  • Lack of patient cooperation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

The Medical University of Gdańsk

Gdansk, 80-210, Poland

RECRUITING

Institute of Cardiology

Warsaw, 04-628, Poland

RECRUITING

MeSH Terms

Conditions

Atrial FibrillationArrhythmias, Cardiac

Condition Hierarchy (Ancestors)

Heart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Lukasz J Szumowski, MD, PhD

    National Institute of Cardiology, Warsaw, Poland

    STUDY CHAIR

Central Study Contacts

Lukasz Szumowski, MD, PhD

CONTACT

Zbigniew Jedynak, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 21, 2010

First Posted

December 23, 2010

Study Start

February 1, 2011

Primary Completion

March 1, 2014

Study Completion

March 1, 2014

Last Updated

February 20, 2013

Record last verified: 2013-02

Locations